SEC Form 4 · accession 0001422996-26-000006
Arcus Biosciences, Inc. · RCUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Juan C. Jaen
Officer — President
Period of report
Jul 9, 2026
Accepted (ET)
Jul 13, 2026 · 5:36 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001724521
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 9, 2026 | S | 48,502 | $30.053 | D | 842,307 | I | By Trust |
| Common StockF1,F3 | Jul 10, 2026 | S | 19,799 | $28.608 | D | 822,508 | I | By Trust |
| Common StockF1,F4 | Jul 10, 2026 | S | 268 | $29.397 | D | 822,240 | I | By Trust |
| Common StockF5 | holding | — | — | — | 378,291 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F4The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F5Includes the unvested portion of the Reporting Person's RSU grants.